Renalytix (RENX) Proxy Filing summary

Executive summary

• The annual general meeting (AGM) is scheduled for December 19, 2024, with nine resolutions proposed, including financial, governance, and compensation matters.

• Shareholders can vote electronically, by proxy, or via CREST, with specific instructions for ADS holders and deadlines for proxy submissions.

• The Board unanimously recommends voting in favor of all resolutions, emphasizing alignment with shareholder interests and company growth.

Voting matters and shareholder proposals

• Resolutions include adoption of annual accounts, approval of the directors' remuneration report, ratification of auditors, authorization of share allotment, disapplication of pre-emption rights, and share repurchases.

• Shareholders have rights to call meetings and submit proposals, with clear deadlines and requirements for 2025 AGM submissions.

• Voting is conducted by poll, with ordinary resolutions requiring a simple majority and special resolutions needing at least 75% approval.

Board of directors and corporate governance

• The Board consists of six directors with diverse backgrounds in life sciences, finance, and innovation.

• Leadership structure separates CEO and Chairman roles to reinforce independent oversight.

• A majority of directors are independent, and all committees are composed of independent members.

• The Board has Audit, Remuneration, and Nomination Committees, each with defined responsibilities and annual charter reviews.

• Board diversity is tracked, and shareholders can recommend or nominate directors.